ICB therapy benefits only a fraction of cancer patients, highlighting the need to identify additional nonredundant checkpoints to improve efficacy and broaden therapeutic applicability.17,115 In our study, SSRI-treated intratumoral T cells exhibited a distinct set of upregulated proliferation/effector-related pathways compared with anti-PD-1-treated T cells (Figures 2 and S2). The gene discussed is PDCD1; the disease is cancer.